Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

64407564MMY4002: PRE-APPROVAL ACCESS Single Patient Request (SPR) TREATMENT GUIDELINE for TALQUETAMAB for Treating Physician Use in Relapsed and Refractory Multiple Myeloma Concurrent With Relapsed and Refractory Light Chain (AL) Amyloidosis

NCT05503550 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT05503550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05503550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
64407564MMY4002: PRE-APPROVAL ACCESS Single Patient Request (SPR) TREATMENT GUIDELINE for TALQUETAMAB for Treating Physician Use in Relapsed and Refractory Multiple Myeloma Concurrent With Relapsed and Refractory Light Chain (AL) Amyloidosis
Lead sponsor
Janssen Research & Development, LLC
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma